Sam68 promotes hepatic gluconeogenesis via CRTC2

Aijun Qiao,Junlan Zhou,Shiyue Xu,Wenxia Ma,Chan Boriboun,Teayoun Kim,Baolong Yan,Jianxin Deng,Liu Yang,Eric Zhang,Yuhua Song,Yongchao C. Ma,Stephane Richard,Chunxiang Zhang,Hongyu Qiu,Kirk M. Habegger,Jianyi Zhang,Gangjian Qin
DOI: https://doi.org/10.1038/s41467-021-23624-9
IF: 16.6
2021-01-01
Nature Communications
Abstract:Hepatic gluconeogenesis is essential for glucose homeostasis and also a therapeutic target for type 2 diabetes, but its mechanism is incompletely understood. Here, we report that Sam68, an RNA-binding adaptor protein and Src kinase substrate, is a novel regulator of hepatic gluconeogenesis. Both global and hepatic deletions of Sam68 significantly reduce blood glucose levels and the glucagon-induced expression of gluconeogenic genes. Protein, but not mRNA, levels of CRTC2, a crucial transcriptional regulator of gluconeogenesis, are >50% lower in Sam68-deficient hepatocytes than in wild-type hepatocytes. Sam68 interacts with CRTC2 and reduces CRTC2 ubiquitination. However, truncated mutants of Sam68 that lack the C- (Sam68 ΔC ) or N-terminal (Sam68 ΔN ) domains fails to bind CRTC2 or to stabilize CRTC2 protein, respectively, and transgenic Sam68 ΔN mice recapitulate the blood-glucose and gluconeogenesis profile of Sam68-deficient mice. Hepatic Sam68 expression is also upregulated in patients with diabetes and in two diabetic mouse models, while hepatocyte-specific Sam68 deficiencies alleviate diabetic hyperglycemia and improves insulin sensitivity in mice. Thus, our results identify a role for Sam68 in hepatic gluconeogenesis, and Sam68 may represent a therapeutic target for diabetes.
What problem does this paper attempt to address?